8results about How to "Enhance antigen presentation" patented technology

The invention discloses a glucan modified bionic nanoparticle as well as a preparation method and application thereof. Preparing nanoparticles based on PLGA as an inner core; the tumor cell membrane is extracted from B16F10 melanoma cells and is used as an outer capsid; glucan is coupled with a hydrophobic long chain through reductive amination and is modified on the surface of a biomimetic nanoparticle cell membrane through a hydrophobic effect. The dextran nano delivery system is successfully constructed, cell membrane specific antigens and dextran are efficiently and jointly delivered to lymph nodes, tumor cell membranes provide epitopes for immune activation of nanoparticles, and beta-dextran provides molecular support for nanoparticle targeting immune cells. In-vivo and in-vitro activity experiments prove that the glycolipid modified bionic nanoparticles can effectively activate innate immunity through macrophages and NK cells, can promote dendritic cell antigen presentation, and initiate potent adaptive immune response. The bionic nanoparticles have huge development potential of novel tumor vaccines, and a new thought is provided for immunotherapy of cancers.

The invention discloses a vaccine based on a protein CAMKII binding domain as well as a preparation method and application of the vaccine. The vaccine based on the protein CAMKII binding domain is a recombinant protein and comprises a CaMKII binding domain protein and an antigen epitope, and the sequence of the CaMKII binding domain protein is as shown in SEQ ID NO. 1. The CaMKII binding domain protein is connected with the nucleotide sequence of the antigen epitope in a gene fusion mode, the recombinant protein is obtained through expression by means of molecular biology, the obtained recombinant protein effectively promotes polarization of macrophages into M1 phenotype and releases more inflammatory cytokines IL-6 to be combined with the antigen epitope, the effect that the antigen is presented by BMDCs is remarkably improved, and the recombinant protein can be applied to the preparation of the antigen. The tumor vaccine provided by the invention has a good application prospect, and can prevent and / or treat cancers.

The invention discloses an engineered adoptive macrophage based on a nano battery as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The preparation method disclosed by the invention comprises the following steps: taking an immunologic adjuvant working solution as a raw material, and obtaining nanoparticles with high drug loading capacity through an assembly effect; as the main energy of ChARM comes from an immunologic adjuvant, the high-drug-loading nano-particle is also called a high-energy-density nano-battery. Diluting the obtained nano particles with a cell culture medium, and co-incubating the diluted nano particles and macrophages to obtain engineered macrophages loaded with the anti-tumor or anti-inflammatory nano battery; the assembly mode is any one of supramolecular assembly, prodrug assembly or metal coordination assembly; the high-density drug-loaded nano battery can endow engineered cells with excellent biological functions. The method solves the technical problems that the preparation of the existing CAR-M is expensive, the gene modification is complex, and the nano-drug delivery system is unstable.

The invention relates to an Ag-DC-CIK cell and application of the Ag-DC-CIK cell in preparation of antitumor drugs, and belongs to the technical field of cell therapy. The Ag-DC-CIK cell is obtained by co-culturing an Ag-DC cell and a CIK cell; the Ag-DC is DC jointly loaded by a WT1 antigen, mucus glycoprotein 1 (MUC1) and Poly (I: C). A WT1 antigen, mucus glycoprotein 1 (MUC1) and Poly (I: C) are jointly loaded on a dendritic cell (DC) to obtain Ag-DC, the Ag-DC and a CIK cell are co-cultured to obtain an Ag-DC-CIK cell, and verification shows that the killing effect on various tumors including cervical cancer, colorectal cancer, gastric cancer and leukemia can be achieved. Moreover, compared with DC-CIK cells obtained by co-culture of non-loaded DC and CIK cells, the DC-CIK cells have the advantage that the killing effect on tumor cells is remarkably improved.

The invention discloses an application of intestinal symbiotic bacteria in preparation of products for preventing and treating colorectal cancer. The intestinal symbiotic bacteria are ruminococcus flavus or succinic acid producing filamentous bacteria. The method has the beneficial effects that the intestinal flora balance can be regulated; the intestinal barrier function can be enhanced; the immunoregulation effect is achieved; the effect of comprehensively preventing and treating colorectal cancer is achieved.

The invention provides a recombinant cell based on mammal reverse transcription protein, a method for delivering an antigen vaccine based on the recombinant cell and application, membrane protein of the recombinant cell is fused with capsid protein PEG10 and antigens, the antigens comprise tumor specific antigens and tumor-associated antigens, the amino terminal of the recombinant cell membrane protein is modified by an adjuvant, and the recombinant cell membrane protein is modified by the adjuvant. The recombinant cell has the functions of activating DC cells, cooperatively promoting tumor neoantigen presentation and activating neoantigen specific T cells to play an anti-tumor role.

The invention designs, optimizes and provides a safe and controllable chimeric antigen receptor loaded with a suicide gene and a macrophage for expressing the chimeric antigen receptor by applying a gene editing technology. The chimeric antigen receptor comprises a single-chain variable region, a hinge region, a transmembrane region and an intracellular signal region of a targeted carcino-embryonic antigen (CEA). The chimeric antigen receptor-Hoxb8 macrophage CAR-Hoxb8-M has the advantages that the chimeric antigen receptor-Hoxb8 macrophage CAR-Hoxb8-M has efficient wettability, the phagocytic ability and antigen presentation ability are enhanced, and the chimeric antigen receptor-Hoxb8 macrophage CAR-Hoxb8-M is expected to become a new strategy for solid tumor cell immunotherapy. The constructed stem progenitor cells are rapid in proliferation, can be massively obtained in a short time, can be cryopreserved for a long time, and are short in macrophage induction cycle, simple and convenient, the macrophages efficiently express CAR and are stable and uniform, small molecule compounds regulate the progenitor cells and macrophage fate, safety and controllability are achieved, and the anti-colorectal cancer treatment effect is achieved. The CAR-Hoxb8-M is combined with an immune checkpoint inhibitor, so that tumor growth can be further inhibited, and the survival rate can be increased.

The application discloses an aptamer-based functionalized nano linker, a preparation method and application, wherein the functionalized nano linker comprises a functionalized nano vesicle as a carrier, the functionalized nano vesicle is a biological nano membrane vesicle prepared through combination treatment of an ICD functionalized biological membrane and a biological membrane carrying an azido group; part of the azido groups of the biological nano membrane vesicle are loaded with an aptamer I for targeting DC cells through alkyne-azido cycloaddition reaction, and the other part of the azido groups are loaded with an aptamer II for targeting T cells through alkyne-azido cycloaddition reaction. The application designs a dual-specific functionalized nano linker, which can simultaneously target and link DC and T cells, the functionalized nano vesicle as the carrier itself has key proteins of ICD effect, can promote maturation of the dendritic cells and antigen cross-presentation, after linking with the T cells, can effectively activate the CD8+ T cells and differentiate the CD8+ T cells to cytotoxicity effect phenotype, and enhance killing of tumor cells.